Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents

Based on in silico screening results, a series of novel 3,5-diarylpyrazoline salicylamide derivatives were designed and synthesized. Compound 25 exhibited the most potent inhibitory activity with an IC50 value of 0.16 μM for BRAFV600E and GI50 value of 0.24 μM for mutant BRAF-dependent WM266.4 melanoma cells.